Regulation: OK After All

Gopal,Kevin;

Article

Pharmaceutical Executive

April 1, 2001

Pharmaceutical Executive

Pharmaceutical Executive-04-01-2001

Volume0

Issue 0

Regulation: OK After All

Author(s):

Kevin Gopal

London-The National Institute of Clinical Excellence (NICE) has decided that Roche's Xenical (orlistat) should be available from the National Health Service for managing obesity and its related problems, but it should not be viewed as a slimming pill.

Articles in this issue

Internet DTC - Minding Your P's & Q's

Regulation: Two-Track Plan

Policy: Tectonic Shift

Liberated?

A Matter of Taste

Partnerships: Bargaining Biotechs

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Regulation: OK After All

Newsletter